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Smad proteins and transforming growth factor-b signaling. It injury is similar to that of kidney development in that
is now generally accepted that transforming growth factor-b each is characterized by cellular proliferation, migration,
(TGF-b) has an important role in the pathogenesis of both and differentiation associated with the expression of “de-acute and chronic forms of renal disease. Although TGF-b’s
velopmentally regulated” genes [2]. Interestingly, follow-potent fibrogenic activity is considered a major factor in chronic
ing acute experimental ischemic injury induced by renalprogression of renal disease, this cytokine participates in the
control of several fundamental cellular responses in the kidney artery clamping, TGF-b expression and activation was
including inflammation, programmed cell death, cell growth, enhanced in proximal tubular papillary proliferations,
cell differentiation, and cellular hypertrophy. Recent identifi-
indicating a role for TGF-b in the final reorganizationcation of Smad proteins as intracellular mediators of TGF-b
of the regenerating tubule [3].signaling has provided important insights into mechanisms that
may determine the specificity of TGF-b action in different renal
and inflammatory cells. Thus, Smads are characterized by an Development, reactivity, and pathophysiology of
astonishingly complex array of molecular and functional inter- blood vessels
actions with other signaling pathways. These emerging patterns
Members of the TGF-b family have diverse chronicof signaling cross talk involving Smad proteins suggest a dy-
and acute effects in the cardiovascular system. Duringnamic profile of positive or negative transmodulation of TGF-b
signaling, depending on the cellular context. Understanding embryogenesis, TGF-bs have prominent roles in de novo
the interplay between these signaling cascades is an important development of blood vessels [4], and in the kidney,
field of investigation that will ultimately reveal new targets for
precisely timed TGF-b signals direct formation of theprecise and selective modulation of TGF-b’s diverse actions
capillary bed in developing glomeruli by steering growth,in renal diseases.
migration, and differentiation of glomerular endothelial
cells [5]. In vitro and in vivo studies demonstrate impor-
tant roles for TGF-b1 in both hypertensive blood vesselMULTIPLE ROLES FOR TGF-b IN THE KIDNEY
remodeling and in the formation of atherosclerotic le-Renal development and acute tubular injury
sions primarily through its effects on vascular smooth
Organogenesis of the metanephric kidney is a precisely muscle cell growth and phenotype [6]. Several observa-
orchestrated process including inductions of an epithelial tions support a role for TGF-b in the acute regulation
structure, the ureteric bud, and a surrounding mesen- of vascular tone. TGF-b induces the vasoconstrictor en-
chyme, the metanephric blastema. Addition of transform-
dothelin 1 (ET-1) and suppresses inducible nitric oxide
ing growth factor-b (TGF-b) to cultured metanephroi in-
synthase (iNOS) resulting in decreased secretion of thehibits tubulogenesis and anti-TGF-b antibodies enhance
vasodilator NO in endothelial cells and vascular smoothnephron formation in cultured metanephroi [1]. To-
muscle cells. In addition, studies by Sharma and cowork-gether with immunolocalization of the TGF-b signaling
ers demonstrate that TGF-b may limit the extent ofsystem in the ureteric bud, these results suggest that
vasoconstrictor stimulation in smooth muscle and mesan-TGF-b may impair induction of tubulogenesis in meta-
gial cells by down-regulating type I inositol 1,4,5-triphos-nephric blastema by the ureteric bud. The process of
phate receptors (IP3R) thus limiting intracellular calciumrestoration of renal tubular integrity after acute tubular
mobilization (see elsewhere in this Supplement and [7]).
These studies point to a role for TGF-b in control of
acute and chronic hemodynamic regulation.1 Present address for M. Schiffer: Department of Medicine IV, Univer-
sity of Erlangen-Nuremberg, D-91054 Erlangen, Germany.
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are underappreciated, considering that TGF-b is more kinases [25] in mesangial cells, and directly activates
MAP kinase (MAPK) pathway signaling through thepotent by a factor of 104 than cyclosporine as an immuno-
extracellular signal-regulated kinases 1 and 2 (ERK1/2)suppressive agent [8]. In this regard, several recent inves-
in macrophage cultures [26] (see also elsewhere in thistigations attempted to explore whether the immunosup-
supplement). In this report, we focus on the function ofpressive activity of TGF-b in immune-mediated renal
Smads in TGF-b signaling and discuss how other signal-disease models is essential to limit the expression of
ing inputs may affect the TGF-b/Smad pathway.immune cell-associated mediators that mediate renal in-
jury. Together, these studies indicate that a primary func-
tion of increased TGF-b in immune-mediated renal in- THE SMAD FAMILY: A BRIEF INTRODUCTION
jury may be to limit the inflammatory response and that TO MEMBER PROTEINS AND FUNCTIONS
blocking TGF-b expression can exaggerate inflammatory Smad signaling pathways have been conserved through-
responses and renal damage [9, 10]. out evolution. Although Smad-related genes Mad and
sma were first discovered using genetic screens in Dro-Glomerulosclerosis and interstitial fibrosis
sophila [27] and Caenorhabditis elegans [28], respec-
Several investigations in many model systems focusing tively, we concentrate our discussion here on vertebrate
on the powerful profibrogenic activities of TGF-b [11–13] Smads that are defined by two Mad protein homology
have led to the paradigm that TGF-b plays a central domains located at the N-terminal (MH1) or C-terminal
role in the pathogenesis of chronic renal lesions such as (MH2) ends, respectively, and a less well-conserved
glomerulosclerosis and interstitial fibrosis. These insights linker region [29]. Nine distinct vertebrate Smad proteins
stem primarily from correlative examination of mesangio- can be classified in three groups [30] (Fig. 1).
proliferative glomerulonephritis induced by the anti-
Receptor-activated Smads (R-Smads)Thy1.1 antiserum [14] or Habu snake venom [15], amino-
R-Smads are defined by a SxS serine motif on thenucleoside nephrosis [16], obstructive nephropathy [17],
C-terminal end where R-Smads are phosphorylated andand diabetic nephropathy [18]. These in vivo results are
activated by type I receptor kinases. The highly similarconsistent with numerous in vitro observations of the
Smad2 and Smad3 interact with TGF-b type I receptorprofibrotic mechanisms induced by TGF-b. Finally, the
or activin type I B receptor, whereas Smad1, Smad5,functional significance of TGF-b as a central mediator
and Smad8 interact with type I receptors of the boneof renal fibrosis is demonstrated by the glomerulosclero-
morphogenetic protein (BMP) receptor subfamily. Thissis and interstitial fibrosis phenotype that develops spon-
pathway specificity is determined by the so-called L3-taneously in TGF-b1 transgenic mice [19]. In addition,
loop in the MH2 domain of R-Smads [31] (Fig. 1).several studies indicate that TGF-b may mediate the
profibrotic effects of angiotensin II [20], cyclosporine Common partner Smad4
[21], and compounds in the “diabetic milieu,” that is,
Following type I receptor induced phosphorylation onglucose [22] and glycated albumin (see elsewhere in this
serines in the SxS motif, R-Smads form heteromeric com-supplement; and [23]).
plexes with the common partner Smad4 (Co-Smad) and
these complexes translocate to the nucleus (Fig. 2). Smad4Understanding the mechanisms of TGF-b signal
was first described as Deleted in Pancreatic Carcinomatransduction will hold the key to a new research field
Locus 4 (DPC4), a candidate tumor suppressor gene [32]focusing on selective modulation of TGF-b actions in
initially thought to be an essential component in all TGF-bthe kidney
signaling responses [33]. Because Smad4 forms complexes
Discussion in the previous section highlights the im- with both, R-Smads in the TGF-b/activin and BMP path-
portance of new research into a molecular understanding ways, it acts as a convergent node and its principal func-
of the intracellular signaling mechanisms that specify tion is to regulate transcription rather than to transmit
diverse cellular responses to TGF-b in renal and inflam- signals [34]. Smad4 shares with both Smad2 and Smad3
matory cells. Recent identification of the Smad family of transcriptional activator function localized in the MH2
intracellular signaling proteins has led to new concepts of domain, and, like Smad3, directly interacts with DNA
the mechanisms that may control the biologic specificity consensus binding sequences (CAGA) [35] through a
of TGF-b’s action in a physiologic or pathophysiologic b-hairpin structure in the MH1 domain (Fig. 1). Another
context. An emerging theme now indicates the impor- shared function of the MH1 domains in Smad2, 3, and
tance of several interactive signaling pathways in addition 4 are autoinhibition by preventing ligand-independent
to Smad signaling pathways downstream from TGF-b re- heteromerizations [36]. Smad–Smad protein interactions
ceptors. For example, TGF-b stimulates protein kinase A require the MH2 domains, respectively. Unlike Smad3
and Smad4, Smad2 has no direct DNA-binding capacity(PKA) pathways [24] and mitogen-activated protein (MAP)
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Fig. 1. The Smad protein family. Phylogenetic tree of vertebrate Smads (except for Xenopus Smad4b [XSmad4b]). Schematic structure/function
diagram illustrates receptor-activated Smads (R-Smad) (example shown here Smad2, 3), common-partner Smads (Co-Smad) (example here Smad4),
and inhibitory Smads (I-Smads)(example here Smad7). MH1and MH2 indicate Mad homology region 1 and 2, respectively. MH1 region mediates
autoinhibition of Smad2, 3, and 4 and DNA binding of Smad3 and 4. MH2 regions include transcriptional activation domains and Smad–Smad
protein interactions in Smad2, 3, and 4, respectively. Phosphorylation sites for Erk/MAPK (Px[S/T]Ps) and type I TGF-b receptors (SxS) are
shown in Smad2/Smad3. Checkered boxes (Smad2) indicate extra exons in Smad2 compared with Smad3. The b-hairpin domain indicates DNA
binding motif in Smad2, 3, and 4. SAD indicates Smad4 activation domain [59]. L3 indicates domain for specificity in type I receptor interaction
(example shown here for TGF-b and activin type I receptors (TbRI/ActR1B)). Right-hand column shows chromosomal map positions for human
Smad2, Smad3, Smad4, and Smad7.
because of the presence of an extra exon in the MH1 Signaling through Smad pathways is controlled by
positive and negative interactions with independentdomain (Fig. 1). Contrary to earlier studies, recent obser-
signaling pathways and dynamic changes ofvations have identified a number of Smad4-independent
cellular structureTGF-b actions [37, 38]. This raises the possibility that as
yet unidentified Co-Smads could mediate certain TGF-b Evidence suggests that Smads are devoid of enzymatic
responses in the absence of Smad4. Indeed, a second activity and that Smad signaling is thus not amplified.
Co-Smad (XSmad4b) has recently been identified in Therefore, regulation of target genes and Smad-induced
Xenopus [39] and several groups are searching for a cellular responses may be sensitive to small changes of
mammalian othologue of XSmad4b. protein levels of Smads, of their subcellular and spatial
compartmentalization, and of their interactions with in-
Inhibitory Smads dependent pathways (Fig. 2). A rational hypothetical
Smad signaling systems are notable for an autoinhibi- model of the control of signaling flow through the Smad
tory feedback loop that involves so-called “inhibitory” pathway can be developed.
Smads (I-Smads). The I-Smads, Smad6 and Smad7, were
Cytoskeletal sequestration of Smads and theirfirst identified in a screen for shear-stress-regulated
recruitment to receptorsgenes in endothelial cells [40] and lack the MH1 domains
of R-Smads and Co-Smads (Fig. 1). These Smads act A recent report shows that unphosphorylated Smad2,
to oppose R-Smads by forming stable interactions with 3, and 4 are bound to intact microtubules in the unacti-
activated type I receptors, thus preventing the phosphor- vated cellular state. Both TGF-b stimulation and disrup-
ylation/activation of R-Smads [41, 42]. At physiologic tion of the microtubular structure induced by cytoskele-
concentrations, Smad6 appears to inhibit BMP signaling tal alterations result in dissociation from b-tubulin and
by interacting with BMP type I receptors and Smad7 inhib- ligand-dependent or ligand-independent phosphoryla-
its TGF-b/activin signaling by interaction with TGF-b/ tion of Smad2 or Smad3 and activation of TGF-b tran-
activin type I receptors, which suggests that the principal scriptional responses [43]. It is possible that after release
functions of Smad6 and Smad7 are to regulate BMP or from cytoskeletal complexes, the R-Smads Smad2 and
Smad3 are then recruited to the TGF-b or activin recep-TGF-b/activin pathways, respectively.
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Fig. 2. Signaling in the TGF-b/Smad pathway
is positively and negatively regulated by inter-
actions with structural cellular elements and con-
verging signaling pathways. Smad2, Smad3, and
Smad4 transmit signals from TGF-b or activin
receptor complexes to the nucleus where they
control transcription of target genes. Critical
features of regulation of the activity of this
pathway include: (a) sequestration of Smads
by intact microtubules in unactivated cells; (b)
release of Smad2 and Smad3 to membrane and
receptor anchored molecules such as SARA in
response to disruption of microtubules and/or
TGF-b signal; (c) recruitment of Smad2 and
Smad3 to activated receptor complexes by
SARA and phosphorylation of R-Smads on
C-terminal serines (Smad2-PP and Smad3-PP);
(d) negative regulation of R-Smad phosphory-
lation by competitive interaction of Smad7
and activated receptor complexes in response
to signaling pathways with opposing activities
(NF-kB and Stat1), and negative autofeed-
back (not shown); and (e) negative regulation
by activated Erk MAP kinase signaling in re-
sponse to growth factors (EGF and HGF) or
oncogenic Ras. These “cross-talking” inter-
plays depend on the cellular context and
modulate the “dosage” of R-Smad/Co-Smad
(Smad2-PP, Smad3-PP, and Smad4) signaling
complexes that translocate to the nucleus in
response to TGF-b. In the nucleus, R-Smad/
Co-Smad complexes interact with different
transcriptional activators and/or repressors ei-
ther independent of or dependent on Smad
binding at specific DNA consensus sequences
in target genes (for an excellent review, see
ten Dijke et al. [30]).
tor complex by interaction with the membrane-associ- (TNF-a) (Fig. 3). Smad7 induced by TNF-a suppresses
TGF-b/Smad signaling through its direct interaction withated protein Smad-anchor for receptor activation (SARA)
the type I receptor on TGF-b ligand-receptor binding.[44] (Fig. 2). SARA is able to present Smad2 and Smad3,
Increased occupancy of activated TGF-b receptor com-but not Smad4, to the activated type I receptors by bind-
plexes by Smad7 results in inhibition of phosphorylation,ing cooperatively to nonphosphorylated Smads and the
nuclear translocation, and DNA binding of R-Smad/receptor complex [44]. An additional level of control of
Co-Smad [46] (Fig. 2). Because it is well documentedaccessibility of R-Smad proteins to activated receptor
that TNF-a inhibits induction of type I collagen synthesiscomplexes is exerted by the regulated synthesis of inhibi-
by TGF-b [47], our observations may provide an impor-tory Smad7. Work by several groups including our own
tant molecular mechanism for negative control of profi-shows that Smad7 competes with R-Smads for access
brotic actions of TGF-b in glomerulosclerosis and inter-to activated TGF-b or activin type I receptors, thereby
stitial fibrosis in the kidney.preventing their phosphorylation [41, 45, 46].
Interestingly, a recent report demonstrates that inhibi-
tion of TGF-b/Smad signaling by interferon (IFN)-g mayInhibition of phosphorylation/activation of R-Smads
also be mediated through increased binding of inhibitoryby opposing signaling pathways
Smad7 and TGF-b receptors, following induction of Smad7
We have demonstrated recently that well-documented expression by the Jak1/Stat1 pathway [48] (Fig. 2). Taken
transmodulation between major opposing signaling path- together, these observations suggest that Smad7 may
ways and the TGF-b/Smad pathway can be mediated function as a general negative regulator of TGF-b recep-
through NF-kB dependent activation of inhibitory Smad7 tor signaling, inasmuch as Smad7 is capable of mediating
[46]. In our report, we show that the NF-kB subunit p65/ both autoinhibitory feedback and down-regulation of
RelA is required for transcriptional activation of Smad7 TGF-b signaling strength by major opposing pathways
by lipopolysaccharides (LPS), and the proinflammatory including the Jak1/Stat1 and the NF-kB pathway (see
schematic in Fig. 2). We propose that inhibition of TGF-bcytokines interleukin-1b and tumor necrosis factor-a
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Fig. 3. Transcriptional activation of Smad7 by TNF-a, IL-1b, and LPS requires NF-kB/RelA. (A) Northern blot analysis of Smad7 transcript
levels in RelA1/1 and RelA2/2 fibroblasts treated with TNF-a (10 ng/ml) or TGF-b (1 ng/ml) for the indicated time periods. (B) RelA1/1 and
RelA2/2 fibroblasts were incubated with TNF-a (10 ng/ml), IL-1b (1 ng/ml), LPS (10 mg/ml), and IFN-g (250 U/ml) for 1 h, respectively. Blots
were probed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to control for RNA loading (with permission to reprint [46]).
receptor signaling function by inhibitory Smad7 may rep- suppression of TGF-b/Smad signaling (Fig. 2). These
observations may provide a mechanism of suppressionresent an effective and general mechanism to alter the
balance between signals with opposing effects on com- of TGF-b/Smad signaling by hyperactivated Ras that
may be operative during tubular regeneration after acuteplex cellular responses including inflammation and cell
proliferation/cell death. tubular injury. In contrast, a different study finds Erk-
dependent phosphorylation of Smad2 at a different motif
Inhibition of nuclear translocation of Smad complexes resulting in increased nuclear translocation and coopera-
by Erk mitogen-activated protein kinases tive signaling with TGF-b/Smad signaling [52].
Reports by several groups indicate a direct interaction
Regulation of Smad protein synthesis and degradationbetween R-Smads and the Erk mitogen-activated protein
(MAP) kinase pathway [49–51]. Activation of Erk MAP We and others find that protein levels of Smad2 and
Smad4 are not regulated by extracellular signals, whereaskinases by epidermal growth factor (EGF) or oncogenic
Ras can lead to phosphorylation of middle linker regions Smad3 is down-regulated following treatment with TGF-b
in some epithelial and mesangial cells [53, 54; Schifferof R-Smads at [S/T]P or Px[S/T]P motifs, resulting in
inhibition of nuclear translocation of these Smads and and Bo¨ttinger, unpublished observations]. Recent reports
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Fig. 4. Molecular mechanism of an intracel-
lular TGF-b autoinhibitory loop. On ligand-
binding and activation of TGF-b receptor com-
plexes, R-Smads Smad2 and Smad3 become
phosphorylated by type I receptor on C-termi-
nal serines and form heterooligomeric com-
plexes with Co-Smad Smad4. After nuclear
translocation, Smad2-PP/Smad3-PP/Smad4
complexes bind to a functional GTCTAGAC
Smad binding element between nucleotides
2179 and 2172 of the human Smad7 pro-
moter and mediate transcriptional activation
of Smad7 by TGF-b. An adjacent imperfect
putative AP-1 protein binding site may in-
teract with AP-1 protein, but its functional
relevance remains to be determined. TGF-b/
Smad-induced synthesis of Smad7 results in
increasing intracellular levels of Smad7 and en-
hanced negative regulation of activated TGF-b
receptor complexes by Smad7 [57].
have examined mechanisms and regulation of turnover/ GENE REGULATION OF INHIBITORY SMAD7
degradation of both cytoplasmic and nuclear Smads. For Given that Smad7 is an inducible intracellular inhibi-
example, the cytoplasmic E3 ubiquitin-ligase SMURF1 tor of TGF-b signaling that is transcriptionally regulated
has been shown to target Smad1 in the BMP-signaling as an immediate-early gene by several signaling pathways
pathway for proteosomal degradation in a ligand-inde- of major importance in renal diseases [40, 46, 49, 56],
pendent manner [54]. It is possible that analogous mech- we cloned the promoter of the human SMAD7 gene
anisms of control of protein degradation of R-Smads and have begun to characterize cis-acting elements and
exist in the TGF-b/activin pathways. However, ubiquitin- transcription factors that control the expression of this
dependent degradation of R-Smads is not only restricted important gene [57]. The human SMAD7 gene consists
to cytoplasmic Smads but may also limit the extend of of 4 exons distributed over approximately 25 kilobases
binding and transcriptional activity of Smad complexes and is located on chromosome 18q21.1 (Susztak and
bound to specific DNA sequence motifs in target gene Bo¨ttinger, unpublished observations; [58]). Within a
promoters [55]. Understanding of the mechanisms that
2303 to 1672 region relative to a major transcription
regulate the ubiquitination-pathways of Smad proteins
start site, we identified a palindromic GTCTAGACmay offer future opportunities to modulate Smad signal-
Smad binding element (SBE) [35] between nucleotidesing activity in a cell or target gene specific manner.
2179 and 2172 that mediates induction of a Smad7
promoter reporter gene by TGF-b. The SBE is locatedTranscriptional regulation of target gene expression by
in close proximity to a putative activator protein (AP)-1Smads involves direct binding of Smads to DNA and
protein binding site. The functional significance of therecruitment of transcriptional (Co-) activator and
putative AP-1 element remains unclear, although prelimi-(Co-) repressor complexes, respectively
nary mobility shift assays indicate that it interacts at leastA rapidly evolving field has been investigating the
with AP-1 family transcription factors (von Gersdorffmechanisms by which Smad proteins direct expression
and Bo¨ttinger, unpublished observations). Our biochem-of target genes of TGF-b signaling. It is now accepted
ical and functional characterization of the SBE demon-that a variety of different mechanisms may cooperate to
strates that TGF-b treatment of cells in culture rapidlyachieve regulated transcription, including direct DNA
induces binding of an endogenous complex of nuclearbinding of R-Smad/Smad4 complexes and interactions
proteins to the SBE that contains Smad2, Smad3, andwith a growing number of DNA-binding or non-DNA-
Smad4 (Fig. 4). In cells that lack either Smad3 or Smad4,binding activators and repressors of transcription (Fig.
no binding of protein complexes to the SBE is detectable.2). This extensive topic is beyond the scope of this review.
These results are consistent with our data obtained fromIt has recently been discussed in an excellent review by
ten Dijke and colleagues [30]. transcriptional reporter gene assays showing that the
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related genes in kidney after ischemic injury: potential role forinduction of the Smad7 promoter requires Smad3 and
TGF-beta in repair. Am J Physiol 275:F894–F903, 1998
Smad4, but not Smad2. A functional role of Smad2 in 4. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson
S, Akhurst RJ: Defective haematopoiesis and vasculogenesis inthe regulation of Smad7 transcription has not yet been
transforming growth factor-beta 1 knock out mice. Developmentdetermined.
121:1845–1854, 1995
Thus, we have identified a molecular mechanism that 5. Pintavorn P, Ballermann BJ: TGF-beta and the endothelium
during immune injury. Kidney Int 51:1401–1412, 1997may have a central role in negative autoregulation of
6. Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, MetcalfeTGF-b/Smad signaling. We propose that ligand-depen-
JC: Transforming growth factor beta decreases the rate of prolifera-
dent activation of TGF-b receptor complexes stimulates tion of rat vascular smooth muscle cells by extending the G2 phase
of the cell cycle and delays the rise in cyclic AMP before entrybinding of Smad2, Smad3, and Smad4 transcription fac-
into M phase. Biochem J 299:227–235, 1994tor complexes to a consensus SBE in the Smad7 pro-
7. Sharma K, Wang L, Zhu Y, Bokkala S, Joseph SK: Transforming
moter. Mutation of the SBE by site-directed mutagene- growth factor-b1 inhibits type I inositol 1,4,5-trisphosphate recep-
tor expression and enhances its phosphorylation in mesangial cells.sis, or deletion of either Smad3 or Smad4, but not Smad2,
J Biol Chem 272:14617–14623, 1997abolishes the ability of TGF-b to activate the Smad7
8. Sporn MB, Roberts AB: Peptide growth factors are multifunc-
promoter. We conclude that transcriptional regulation tional. Nature 332:217–219, 1988
9. Meyers CM, Kelly CJ: Immunoregulation, TGF beta 1. Suppres-of Smad7 by TGF-b itself is mediated through rapid and
sion of a nephritogenic murine T cell clone. Kidney Int 46:1295–direct Smad3-and Smad4-dependent signaling and tran-
1301, 1994
scriptional activation. Our observations are consistent 10. Kitamura M, Suto TS: TGF-beta and glomerulonephritis: anti-
inflammatory versus prosclerotic actions. Nephrol Dial Transplantwith a report indicating that Smad3 and Smad4 interact
12:669–679, 1997with and activate the murine Smad7 promoter [56].
11. Border WA, Noble NA: Transforming growth factor beta in tissue
Interestingly, our studies indicate that TNF-a and IFN-g fibrosis. N Engl J Med 331:1286–1292, 1994
12. Ziyadeh FN: Role of transforming growth factor beta in diabeticmay regulate the SMAD7 gene through cis- and trans-
nephropathy. Exp Nephrol 2:137–137, 1994acting factors that are distinct from the SBE and Smads,
13. Bitzer M, Sterzel RB, Bottinger EP: Transforming growth fac-
respectively. Thus, we provide evidence for a model in tor-b in renal disease. Kidney Blood Press Res 21:259–261, 1998
14. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahtiwhich the overall level of Smad7 gene expression may be
E: Suppression of experimental glomerulonephritis by antiserumdetermined by combined activation of distinct regulatory against transforming growth factor beta 1. Nature 346:371–374,
elements in the Smad7 promoter in response to distinct 1990
15. Barnes JL, Abboud HE: Temporal expression of autocrine growthsignaling pathways. Ongoing investigations in our labo-
factors corresponds to morphological features of mesangial prolif-ratory focus on the localization of functional Stat1 and eration in Habu snake venom-induced glomerulonephritis. Am J
NF-kB/RelA regulatory elements in the Smad7 gene to Pathol 143:1366–1376, 1993
16. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA:map the molecular determinants of transcriptional acti-
Renal extracellular matrix accumulation in acute puromycinvation of SMAD7 by TNF-a and IFN-g. We anticipate aminonucleoside nephrosis in rats. Am J Pathol 141:1381–1396,
that the continued investigation of Smad7 and related 1992
17. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-b1molecules may lead to novel approaches in the design
mRNA in the obstructed kidney of rats with unilateral ureteralof inhibitors of TGF-b signaling for therapeutic use in ligation. Kidney Int 44:313–321, 1993
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